Literature DB >> 26616166

Biological and immunological characterization of norovirus major capsid proteins from three different genotypes.

Yuqi Huo1, Xin Wan2, Tong Ling2, Shuo Shen3.   

Abstract

Noroviruses (NoVs) are the leading cause of non-bacterial acute gastroenteritis worldwide. Due to a lack of cell culture system and animal model, our understanding of NoVs has been lagging behind. In this study, NoV major capsid proteins (VP1) from three different genotypes (GI.2, GII.3 and GII.4) were expressed by using recombinant baculovirus expression system and which led to successful assembly of virus-like particles (VLPs). The receptor binding patterns of three kinds of VLPs were characterized by using synthetic and salivary HBGA-VLP binding assay. Cross-reactivity and cross-blocking activity of rabbit hyperimmune sera against these VLPs were determined by ELISA/Western blot analysis and saliva-VLP binding blockade assay, respectively. Expression of the major capsid proteins from three genotypes all led to smaller VLPs in dominance when sf9 cells were cultured in suspension, which was in consistence with our previous report. These smaller VLPs were used for in vitro synthetic and salivary HBGA-VLP binding and binding blockade assays. VLPs from GII.3 strain exhibited no binding to all synthetic HBGAs and saliva samples tested while VLPs from GI.2 and GII.4 strain showed similar binding pattern and bound to all salivary HBGAs tested. Rabbit anti-GII.3 VLPs hyperimmune serum didn't block the binding of GI.2 and GII.4 VLPs to salivary HBGAs while rabbit anti-GI.2 VLP hyperimmune serum blocked the binding of GII.4 VLPs to salivary HBGAs but not vice versa. Our results provide further evidence indirectly in support of presence of other factors involved in receptor binding other than HBGAs for NoVs, and demonstrate poor cross-blocking activities of antibodies against VLPs within or across genogroups.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Blocking antibody; HBGAs; Hyperimmune sera; Norovirus; VLPs

Mesh:

Substances:

Year:  2015        PMID: 26616166     DOI: 10.1016/j.micpath.2015.11.022

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  5 in total

1.  Characterization of virus-like particles derived from a GII.3 norovirus strain distantly related with current dominating strains.

Authors:  Yuqi Huo; Xuhui Chen; Lijun Zheng; Jinling Huo; Shanfeng Zhang; Mingchen Wang; Yumei Wang
Journal:  Virus Genes       Date:  2016-05-27       Impact factor: 2.332

2.  Genomic and biological characterization of a pandemic norovirus variant GII.4 Sydney 2012.

Authors:  Lili Ge; Xuhui Chen; Jinjin Liu; Lijun Zheng; Chongfen Chen; Shuying Luo; Pengbo Guo; Jinghui Kong; Yinsen Song; Yuqi Huo
Journal:  Virus Genes       Date:  2020-01-07       Impact factor: 2.332

3.  Linear epitope binding antibodies against GII.3 Norovirus exhibit no histo-blood group antigens (HBGAs) blocking effects.

Authors:  Shuhuan Ma; Fukun Zhang; Lijun Zheng; Jinjin Liu; Jie Ma; Xuhui Chen; Zhaojie Yang; Wenhui Wang; Li Li; Mingchen Wang; Yuqi Huo
Journal:  Virus Genes       Date:  2019-02-06       Impact factor: 2.332

Review 4.  Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens.

Authors:  Eunüs S Ali; Harinda Rajapaksha; Jillian M Carr; Nikolai Petrovsky
Journal:  Antiviral Res       Date:  2016-07-13       Impact factor: 5.970

5.  Identification of Human Norovirus GII.3 Blockade Antibody Epitopes.

Authors:  Yufang Yi; Shuxia Wang; Xiaoli Wang; Pei Xiong; Qingwei Liu; Chao Zhang; Feifei Yin; Zhong Huang
Journal:  Viruses       Date:  2021-10-13       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.